
|Articles|November 15, 2002
Second Course
Efalizumab retreatment works as effectively as original treatmentPhysician: Kim A. Papp, M.D.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
5











